Diasorin S.p.a. · MIL:DIA
Diasorin — Q3 2025 Earnings Presentation
23 slides from Diasorin's earnings presentation, Nov 5, 2025
Slide 1: Q3 & 9M 2025 Results
XY Oiasorin Q3 & 9M 2025 RESULTS November 5, 2025
Slide 2: Disclaimer
DISCLAIMER In General. This disclaimer applies to this presentation and any No distribution of this Presentation. This Presentation is being oral comments of any person presenting it. This document, furnished to you solely for your information and may not be taken together with any such oral comment
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Dias
Slide 4: 9M 2025 Key Facts
9M 2025 KEY FACTS +) Diasorin
Slide 5: 9M 2025 Key Facts
9M 2025 KEY FACTS IMMUNODIAGNOSTICS ▪ MeMed: new evidence presented at ACEP 2025 on the role of MeMed BV in supporting clinical decision-making in emergency medicine ▪ TSH-R Ab: launch of a test designed to improve the diagnosis of Graves’ disease, in all CE-mark accepting countries ▪ US Hospital St
Slide 6: Financial Highlights
FINANCIAL HIGHLIGHTS +) Diasorin
Slide 7: Q3'25 & 9M'25 Revenue Variances at Constant Exchange Rates 2024
Q3’25 & 9M’25 Revenue Variances at Constant Exchange Rates 2024 Q3 Group revenues (figures in €/million) 9M Group revenues (figures in €/million) Note: YoY variations are presented using 2024 constant exchange rates. Both absolute figures and percentages are rounded to the nearest whole number 7 Ind
Slide 8: Q3'25 & 9M'25 Immunodiagnostic Revenue Variances
Q3’25 & 9M’25 Immunodiagnostic Revenue Variances At Constant Exchange Rates 2024 Q3 revenues (figures in €/million) 9M revenues (figures in €/million) Base Business (excluding outbreaks and China): China: • Testing volumes decelerated in Q3’25 in Europe • Onset of the second wave of VBP • By region:
Slide 9: Q3'25 & 9M'25 Molecular Diagnostic Revenue Variances
Q3’25 & 9M’25 Molecular Diagnostic Revenue Variances At Constant Exchange Rates 2024 Q3 revenues (figures in €/million) 9M revenues (figures in €/million) Lowplex Multiplex Lowplex Multiplex Automated multiplexing: LIAISON MDX targeted: • Business impacted by flu seasonality due to current menu limi
Slide 10: LIAISON MDX
LIAISON MDX Targeted • Annualized book of business: approx. € 40 million • Approx. +40% both in Q3’25 and 9M’25 • Continued strong momentum, with growth driven by specialty tests (e.g., C. auris, cCMV) ASR • Annualized book of business: approx. € 40 million • Approx. -2% in Q3’25 and approx. +2% in
Slide 11: LIAISON PLEX
LIAISON PLEX Commercial launch update: • Successfully secured a major contract with Quest Diagnostics • Leading U.S. hospital laboratories are adopting the platform for its flexibility, developing a set number of fully customized “base panels” tailored to different patient populations or using credi
Slide 12: LIAISON NES
LIAISON NES Market positioning • LIAISON NES is intended to serve both the hospitals and POLs markets in the U.S. Regulatory Submission • The platform and its first 4-plex respiratory panel (Flu A, Flu B, COVID-19, RSV) have been submitted to the FDA for 510(k) clearance and CLIA Waiver Clearance •
Slide 13: Q3'25 & 9M'25 LTG Revenue Variances
Q3’25 & 9M’25 LTG Revenue Variances At Constant Exchange Rates 2024 Q3 revenues (figures in €/million) 9M revenues (figures in €/million) -15% -10% +3% +20% Life Science clients: • Performance impacted by unfavorable market conditions Diagnostics clients: • Strong performance in the first six months
Slide 14: Q3 & 9M 2025 Profitability Profile
Q3 & 9M 2025 Profitability Profile Net Revenues and Adj. EBITDA data @ current exchange rates; Adj. EBITDA Margin @ constant exchange rates. 33% 32% 287 280 In Q3 2025, Adjusted1 EBITDA2 Margin was equal to 32% @ CER, mainly due to tariff impacts and an unfavorable technology/geography sales mix. 94
Slide 15: FY 2025 Company Guidance
FY 2025 COMPANY GUIDANCE +) Diasorin
Slide 16: FY'25 Guidance Revised
FY’25 Guidance revised FY’25 GUIDANCE (@CER 2024) • Ex-COVID revenues: approx. +5%, approx. +4% including COVID revenues (equal to approx. 10 €/mln) • Adjusted1 EBITDA2 Margin: approx. 33% 1 With reference to the Adjusted EBITDA, Adjusted EBIT and Adjusted Net Profit indicators, please refer to the
Slide 17: Financial Schemes
FINANCIAL SCHEMES +) Diasorin
Slide 18: Income Statement
Income Statement 9M Q3 Amounts in millions of euros 2024 2025 2024 2025 Net Revenues 876 900 287 280 Cost of sales (299) (313) (99) (99) Gross profit 578 587 188 181 66% 65% 65% 65% Sales and marketing expenses (211) (212) (70) (69) Research and development costs (65) (70) (22) (23) General and admi
Slide 19: Balance Sheet
Balance Sheet Amounts in millions of euros 12/31/2024 09/30/2025 Change Goodwill and intangibles assets 2,028 1,798 -230 Property, plant and equipment 271 261 -11 Other non-current assets 34 39 +5 Net working capital 346 330 -16 Other non-current liabilities (264) (241) +22 Net Invested Capital 2,41
Slide 20: Cash Flow Statement
Cash Flow Statement 9M Q3 Amounts in millions of euros 2024 2025 2024 2025 Cash and cash equivalents at the beginning of the period 280 344 170 173 Cash provided by operating activities 286 260 131 115 Cash provided/(used) in investing activities (37) (108) (26) (80) Cash provided/(used) in financin
Slide 21: 9M'25 Reconciliation to Consolidated Financial Statements
9M’25 Reconciliation to Consolidated Financial Statements Amounts in millions of euros Gross Profit EBITDA EBIT Net Result Financial Statements Measures 587 291 194 137 % on Revenues 65% 32% 22% 15% Adjustments “One-off” costs related to integration and restructuring of non recurring - 11 11 11 even
Slide 22: 9M'24 Reconciliation to Consolidated Financial Statements
9M’24 Reconciliation to Consolidated Financial Statements Amounts in millions of euros Gross Profit EBITDA EBIT Net Result Financial Statements Measures 578 289 193 141 % on Revenues 66% 33% 22% 16% Adjustments “One-off” costs related to the integration and restructuring of Luminex - 3 3 3 Depreciat
Slide 23: Slide 23